Vaxcyte appoints vaccine industry veteran Moncef Slaoui to board

Filed June 23, 2026 · Period ending June 17, 2026 · ~1 min read

Key Changes

• medium

  Moncef Slaoui appointed as Class II director effective June 17, 2026, with term expiring at 2028 annual meeting. Board determined he qualifies as independent under Nasdaq rules.

  Item 5.02 verify on EDGAR →
• low

  Jacks Lee retired from the Board effective June 17, 2026. Retirement was not due to any disagreement with the Company; Lee entered consulting agreement to advise on global supply and manufacturing.

  Item 5.02 verify on EDGAR →
• low

  Slaoui will receive standard non-employee director compensation with annual equity grant value of $430,000, consistent with the Company's director compensation program.

  Item 5.02 verify on EDGAR →